NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Frost & Sullivan
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Lauds SnooZeal’s Unique Electrical Stimulation Therapy for Sleep Apnea in the European Market - SnooZeal offers superior value to patients by addressing both sleep apnea and snoring - SnooZeal.com / Frost.com
Frost & Sullivan Lauds SnooZeal’s Unique Electrical Stimulation Therapy for Sleep Apnea in the European Market

 

NewswireToday - /newswire/ - London, United Kingdom, 2017/02/22 - SnooZeal offers superior value to patients by addressing both sleep apnea and snoring - SnooZeal.com / Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services / Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the sleep apnea therapy market, Frost & Sullivan recognizes SnooZeal, Inc. with the 2017 European New Product Innovation Award. SnooZeal is a highly innovative product that intelligently addresses the root causes of sleep apnea by training the tongue muscles through the clinically proven continuous transmucosal electrical stimulation therapy. Because of its over-the-counter (OTC) status, SnooZeal is one of the most accessible anti-snoring products available in the market today. This ease of access has enabled the company to build a clear competitive advantage in terms of early market access.

Unlike competitive anti-snoring therapies widely prescribed as viable treatment options for sleep apnea patients, SnooZeal’s product is based on the simple principle of electrically stimulating the tongue muscles in a non-invasive manner to exercise the over-relaxed muscles. SnooZeal is the only product in the European market used as a therapy during waking hours, enhancing patient convenience and adherence. To be cured of various stages of sleep apnea, the user needs to wear the mouthpiece for at least 20 minutes twice a day for a minimum of 6 weeks.

“The device is designed to accommodate the treatment needs of patients suffering from various degrees of sleep-disordered breathing by optimizing treatment parameters, which are clinically demonstrated to deliver best results and autonomy to patients,” said Frost & Sullivan Industry Analyst Arjunvasan Ambigapathy. “SnooZeal anti-snoring therapy helps patients consciously correct their symptoms, which is clinically demonstrated to be more effective than therapies that are administered when the patient is unconscious. SnooZeal is the only therapeutic option aimed at reversing the cause of this condition, a value that is not seen in most widely-prescribed products in the market today.”

One of SnooZeal’s most innovative features is its simple design comprising three components:

• a wearable mouthpiece in the form of a glove that fits onto the tongue;
• a rechargeable control unit attached to the mouthpiece through a mini-USB connection;
• a remote control unit and a smartphone app to manage various treatment parameters that are ideal for patients.

When designing the mouthpiece, SnooZeal's team worked with various dentists and maxillofacial surgeons to ensure the product is flexible enough to cover and fit various tongue sizes, without restricting its potential for OTC sales across specific geographies. The product’s ease of use; enhanced mobile connectivity; and better collaboration with care providers before, during, and after the therapy have made SnooZeal a truly user-friendly, innovative medical device.

Within a year of its inception, SnooZeal received commercial approval from European healthcare authorities to offer its product OTC as a clinically safe and effective alternative to sleep apnea therapy. The product is awaiting approval from the Food and Drug Administration (FDA) and will soon be available in the United States, which had subsequently garnered the attention of leading investors.

“Being CE-approved for sale in the European market, SnooZeal aims to present its products across both retail and online channels in the United Kingdom, Germany, Switzerland, France, and other major European economies in the near future,” noted Arjunvasan Ambigapathy. “With plans to expand its market across emerging economies such as Russia, Mexico, India, China, Canada, and Brazil, SnooZeal's net market value could be higher than most medical device companies in this emerging industry sector and most other companies operating within the European market today.”

For successfully meeting the core customer requirements of quality, functionality, clinical effectiveness, and reliability, SnooZeal’s sleep apnea product richly deserves Frost & Sullivan’s honour.

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the product’s value-added features/benefits and the increased return on investment (ROI) it offers customers, which in turn raise customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About SnooZeal, Inc.
SnooZeal’s antisnoring and sleep apnea device (snoozeal.com) scored a CE mark, making it the first commercially available over-the-counter device that targets the underlying cause of snoring.

The SnooZeal device addresses the excessive relaxation and loss of tongue muscle tone during sleep. The device is worn for 20 to 25 minutes twice a day over six weeks. It delivers electric pulses to the back of the tongue to increase muscle tone with the goal of reversing the over-relaxation of the tongue during sleep. The patient uses a smartphone app to control the treatment.

The daytime treatment differentiates SnooZeal from currently available treatments that are used at night.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that could make or break today's market participants. For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the Discussion.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services / Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services / Equipment articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Lauds SnooZeal’s Unique Electrical Stimulation Therapy for Sleep Apnea in the European Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Chiara Carella - Frost.com 
+44(0)20 7343 8314 chiara.carella[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Medical Services / Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Medical Services / Equipment Most Recent Related Newswires:

LifeOmic Applauded by Frost & Sullivan for Enabling More Cost-efficient, Targeted Holistic Precision Health with its Interoperable Precision Health So
Bruker and TOFWERK Form Strategic Partnership in High-Speed, Ultra-Sensitive Solutions for Applied and Industrial Markets
Bruker Launches Novel 7 Tesla and 9.4 Tesla Preclinical MRI Magnets
Withings Health Solutions Brings Simplicity and Enhanced Patient Experience to the Core of its New Enhanced Remote Patient Monitoring Solution
Bruker Launches Minispec Droplet Size Analyzer 2.0 for Food and Cosmetic Applications
Bruker Advances Biomolecular Research with GHz-Class NMR Announces New Capabilities for High-Performance Fourier 80
Bruker Demonstrates Novel and Unique Compact 1.0 GHz NMR Magnet
Bruker Announces Key Innovations for Multiplexed Spatial Proteomics and Unbiased Multiomic Imaging for Cancer Research
Bruker Launches Benchtop FT-NMR Solution for Forensic Narcotics Analysis
Bruker Acquires Optimal Companies for Pharma PAT Software and Biopharma Manufacturing Automation Expertise and Technologies
IBA and Tractebel Agree on Partnership to Support Proton Therapy Construction Projects
SCHOTT and Hungarian Government Invest in Cutting-edge Syringe Production
Bruker Releases CCS-Enabled TIMScore™ and TIMS DIA-NN 4D Proteomics Software
C2i Genomics Applauded by Frost & Sullivan for Enabling Real-time Cancer Monitoring Using Genomic Data with its C2intelligence Platform
XACT Robotics® Lauded by Frost & Sullivan for Improving CT-guided Percutaneous Procedures with its Breakthrough Hands-Free Robotic System

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Limelon Advertising, Co.





 
  ©2022 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)